PCSK9 and familial hypercholesterolemia: Given that bempedoic acid is also indicated for patients with familial hypercholesterolemia or established ASCVD [47], this agent might be seen as most helpful in those who are unable to receive subcutaneous injections, given the much lower degree of LDL-C reduction attainable with bempedoic acid as compared with PCSK9 inhibitors.